Deutsche Bank Initiates Coverage On Sarepta Therapeutics with Buy Rating, Announces Price Target of $109
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Neena Bitritto-Garg has initiated coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Buy rating and set a price target of $109.
December 12, 2023 | 9:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Deutsche Bank initiated coverage on Sarepta Therapeutics with a Buy rating and a price target of $109, which could positively influence investor sentiment and the stock's performance.
Analyst ratings, especially from major banks like Deutsche Bank, can significantly impact stock prices. A Buy rating suggests a positive outlook, potentially leading to increased investor interest and a rise in stock price. The announcement of a price target above the current market price further reinforces the positive sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100